Evidence map›Paper›PMID 41680658›Full record

ArticleBMC cancer2026

Nomogram-based prediction of checkpoint inhibitor pneumonitis in lung cancer patients.

Dan Tao, Haike Lei, Lisi Sun, Lulu Wang, Wei Zhou, Ying Wang, Yongzhong Wu

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dan Tao *Department of Radiation Oncology, Chongqing University Cancer Hospital, 181, Hanyu Road, Shapingba District, Chongqing, 400030, China.
Haike Lei *Chongqing Cancer Multi-omics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, Chongqing, China.
Lisi SunDepartment of Radiation Oncology, Chongqing University Cancer Hospital, 181, Hanyu Road, Shapingba District, Chongqing, 400030, China.
Lulu WangDepartment of Radiation Oncology, Chongqing University Cancer Hospital, 181, Hanyu Road, Shapingba District, Chongqing, 400030, China.
Wei ZhouDepartment of Radiation Oncology, Chongqing University Cancer Hospital, 181, Hanyu Road, Shapingba District, Chongqing, 400030, China.
Ying WangDepartment of Radiation Oncology, Chongqing University Cancer Hospital, 181, Hanyu Road, Shapingba District, Chongqing, 400030, China. yingwangcq@hotmail.com.
Yongzhong WuDepartment of Radiation Oncology, Chongqing University Cancer Hospital, 181, Hanyu Road, Shapingba District, Chongqing, 400030, China. cqmdwyz@163.com.

Funding

Chongqing Science and Health Joint Medical Research Project No. 2023GGXM002National Natural Science Foundation Project 81972857National Natural Science Foundation Project 82073347
6 · The paper itself

Abstract

backgroundCheckpoint inhibitor pneumonitis (CIP) is an uncommon but clinically severe adverse event that can seriously compromise the quality of life and can be potentially life-threatening in lung cancer patients receiving immune checkpoint inhibitors (ICI). However, there is still a lack of effective predictive models to predict the occurrence of CIP. The aim of this study was to develop a novel scoring system for predicting the risk of CIP based on a nomogram model.

methodsWe retrospectively screened patients with lung cancer who received ICI treatment at our hospital. The independent risk factors of CIP were identified by the univariable and multivariable analysis of the COX hazard regression model and were integrated to develop a nomogram predictive model. The receiver operating characteristic (ROC) curve, the concordance index (C- index), and the calibration curve were used to evaluate the discrimination and prediction accuracy of the model. The clinical utility of the model was evaluated by decision curve analysis (DCA).

resultsA total of 2082 cancer patients were included in the analysis. In the final multivariate Cox regression analysis identified that sex, body mass index (BMI), chemotherapy, radiotherapy, C-reactive protein (CRP), CD4/CD8, white blood cell (WBC), ALB/GLB, platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), neutrophil-to-platelet ratio (NPR), platelet-to-albumin ratio (PAR), and CRP-to-lymphocyte ratio (CLR) were the independent predictive factors for CIP. Based on these risk factors, a predictive nomogram model was constructed. The C-index for the nomogram model in predicting the probability of CIP at 1 year, 1.5 years, and 2 years was 0.704, 0.718, and 0.725, respectively. The average C-index (SD) was 0.712 (0.004), and the average AUC (SD) was 0.733 (0.005), calculated through 100 iterations of 10-fold cross-validation. The calibration curves demonstrated good concordance, and the DCA indicated that the model had good clinical utility.

conclusionsThe nomogram was accurate in predicting the occurrence of CIP in patients with lung cancer. This study provides a reference for screening CIP high-risk patients and for individualized treatment strategies.

Indexed as

Immune Checkpoint InhibitorsLung NeoplasmsNomogramsPneumoniaAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsROC CurveImmune Checkpoint InhibitorsCheckpoint inhibitor pneumonitisLung cancerNomogramPrediction modelToxicity

Identifiers

PMID41680658
PMCPMC13005533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.